Group 1 - The company does not engage in vaccine development, specifically for HIV vaccines [2] - The main business of the company is the research, production, and sales of blood products [2] - The company operates in the blood products industry, with key products including human albumin, human immunoglobulin, and human coagulation factors, as well as recombinant coagulation factor products [2]

Group 1 - The stock price of Kehua Bio reported at 7.00 yuan as of August 4, 2025, with an increase of 0.16 yuan, representing a rise of 2.34% compared to the previous trading day [1] - The trading volume on the same day was 307,075 hands, with a transaction amount reaching 212 million yuan [1] - Kehua Bio operates in the medical device industry, focusing on the research, production, and sales of in vitro diagnostic reagents and medical instruments [1] Group 2 - The company's product line includes various fields such as clinical biochemistry, immunodiagnostics, and molecular diagnostics [1] - A recent clinical trial for an HIV vaccine using the "Tian Tan strain" smallpox virus as a carrier has been completed, marking a significant development in the industry [1] - Industry experts anticipate that the HIV vaccine market will reach a commercialization turning point between 2025 and 2030, drawing market attention to Kehua Bio as a related concept stock [1] Group 3 - On August 4, Kehua Bio experienced a net outflow of main funds amounting to 3.1058 million yuan, which accounts for 0.09% of its circulating market value [1] - Over the past five trading days, the cumulative net outflow reached 19.6009 million yuan, representing 0.54% of its circulating market value [1]